Targets for active immunotherapy against pediatric solid tumors

Cancer Immunology, Immunotherapy

Volumn 58, Issue 6, 2009, Pages 831-841

  Jacobs, J F M ^a,c   Coulie, P G ^b   Figdor, C G ^c   Adema, G J ^c   De Vries, I J M ^c   Hoogerbrugge, P M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DE DUVE INSTITUTE   (Belgium)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigen; Cancer; Immunotherapy; Pediatrics

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CHIMERIC PROTEIN; DENDRITIC CELL VACCINE; DIFFERENTIATION ANTIGEN; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GANGLIOSIDE; GANGLIOSIDE ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 13 RECEPTOR; MAGE 3 A1 PEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; MONOCLONAL ANTIBODY; PROTEIN P53; RECOMBINANT ALPHA INTERFERON; RECOMBINANT HORMONE; RECOMBINANT INTERLEUKIN 2; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; RNA BINDING PROTEIN EWS; T LYMPHOCYTE ANTIGEN; TOXIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; ACUTE LYMPHOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; ASTROCYTOMA; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG TARGETING; EPENDYMOMA; EPSTEIN BARR VIRUS; EWING SARCOMA; GENE MUTATION; GENE TRANSLOCATION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN HERPESVIRUS 8; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VIVO STUDY; INNATE IMMUNITY; KAPOSI SARCOMA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LYMPHOMA; MEDULLOBLASTOMA; MELANOMA; METASTASIS; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CANCER; RHABDOMYOSARCOMA; SOLID TUMOR; TISSUE SPECIFICITY; TUMOR CELL DESTRUCTION; TUMOR GENE; TUMOR REJECTION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; WART VIRUS;

ANTIGENS, NEOPLASM; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS;

EID: 63949086087     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0619-x     Document Type: Article

References (139)

1. C Adida D Berrebi M Peuchmaur M Reyes-Mugica DC Altieri 1998 Anti-apoptosis gene, survivin, and prognosis of neuroblastoma Lancet 351 882 883
2. N Aldosari SH Bigner PC Burger L Becker JL Kepner HS Friedman RE McLendon 2002 MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group Arch Pathol Lab Med 126 540 544
3. G Amir J Issakov I Meller E Sucher A Peyser IJ Cohen I Yaniv MW Ben Arush U Tavori Y Kollender N Ron N Peylan-Ramu 2002 Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: correlation with clinical outcome Hum Pathol 33 170 174
4. A Anichini C Maccalli R Mortarini S Salvi A Mazzocchi P Squarcina M Herlyn G Parmiani 1993 Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients J Exp Med 177 989 998
5. AM Asemissen U Keilholz S Tenzer M Muller S Walter S Stevanovic H Schild A Letsch E Thiel HG Rammensee C Scheibenbogen 2006 Identification of a highly immunogenic HLA-A01-binding T cell epitope of WT1 Clin Cancer Res 12 7476 7482
6. I Ayan O Dogan R Kebudi B Bavbek C Alatli S Dervisoglu R Disci M Demiryont 1997 Immunohistochemical detection of p53 protein in rhabdomyosarcoma: association with clinicopathological features and outcome J Pediatr Hematol Oncol 19 48 53
7. CN Baxevanis NN Sotiriadou AD Gritzapis PA Sotiropoulou SA Perez NT Cacoullos M Papamichail 2006 Immunogenic HER-2/neu peptides as tumor vaccines Cancer Immunol Immunother 55 85 95
8. J Bayani M Zielenska P Marrano Y Kwan Ng MD Taylor V Jay JT Rutka JA Squire 2000 Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping J Neurosurg 93 437 448
9. E Biagi C Bollard R Rousseau M Brenner 2003 Gene Therapy for Pediatric Cancer: State of the Art and Future Perspectives J Biomed Biotechnol 2003 13 24
10. B Bodey B Bodey Jr SE Siegel 1995 Immunophenotypic characterization of infiltrating polynuclear and mononuclear cells in childhood brain tumors Mod Pathol 8 333 338
11. B Bodey SE Siegel HE Kaiser 2002 MAGE-1, a cancer/testis-antigen, expression in childhood astrocytomas as an indicator of tumor progression In Vivo 16 583 588
12. T Boon J Van Snick A Van Pel C Uyttenhove M Marchand 1980 Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis J Exp Med 152 1184 1193
13. T Boon JC Cerottini B Van den Eynde P van der Bruggen A Van Pel 1994 Tumor antigens recognized by T lymphocytes Annu Rev Immunol 12 337 365
14. T Boon PG Coulie B Van den Eynde 1997 Tumor antigens recognized by T cells Immunol Today 18 267 268
15. T Boon PG Coulie BJ Van den Eynde P van der Bruggen 2006 Human T cell responses against melanoma Annu Rev Immunol 24 175 208
16. L Bowman M Grossmann D Rill M Brown WY Zhong B Alexander T Leimig E Coustan-Smith D Campana J Jenkins D Woods G Kitchingman E Vanin M Brenner 1998 IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma Blood 92 1941 1949
17. GM Brodeur RC Seeger M Schwab HE Varmus JM Bishop 1984 Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage Science 224 1121 1124
18. PJ Browett HM Cooke LM Secker-Walker JD Norton 1989 Chromosome 22 breakpoints in variant Philadelphia translocations and Philadelphia-negative chronic myeloid leukemia Cancer Genet Cytogenet 37 169 177
19. DA Caruso LM Orme AM Neale FJ Radcliff GM Amor W Maixner P Downie TE Hassall ML Tang DM Ashley 2004 Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer Neuro Oncol 6 236 246
20. IY Cheung NK Cheung 1997 Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma Clin Cancer Res 3 821 826
21. IY Cheung NK Cheung 2001 Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE Med Pediatr Oncol 36 210 212
22. DD Chi RE Merchant R Rand AJ Conrad D Garrison R Turner DL Morton DS Hoon 1997 Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas Am J Pathol 150 2143 2152
23. LJ Cooper 2008 Adoptive cellular immunotherapy for childhood malignancies Bone Marrow Transplant 41 183 192
24. JA Coronella C Spier M Welch KT Trevor AT Stopeck H Villar EM Hersh 2002 Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast J Immunol 169 1829 1836
25. MV Corrias P Scaruffi M Occhino B De Bernardi GP Tonini V Pistoia 1996 Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma Int J Cancer 69 403 407
26. R Dagher LM Long EJ Read SF Leitman CS Carter M Tsokos TJ Goletz N Avila JA Berzofsky LJ Helman CL Mackall 2002 Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study Med Pediatr Oncol 38 158 164
27. P Dalerba E Frascella B Macino S Mandruzzato A Zambon A Rosolen M Carli V Ninfo P Zanovello 2001 MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas Int J Cancer 93 85 90
28. E de Alava CR Antonescu A Panizo D Leung PA Meyers AG Huvos FJ Pardo-Mindan JH Healey M Ladanyi 2000 Prognostic impact of P53 status in Ewing sarcoma Cancer 89 783 792
29. S De Vleeschouwer F Van Calenbergh P Demaerel P Flamen S Rutkowski E Kaempgen JE Wolff C Plets R Sciot SW Van Gool 2004 Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report J Neurosurg 100 492 497
30. S De Vleeschouwer S Fieuws S Rutkowski F Van Calenbergh J Van Loon J Goffin R Sciot G Wilms P Demaerel M Warmuth-Metz N Soerensen JE Wolff S Wagner E Kaempgen SW Van Gool 2008 Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme Clin Cancer Res 14 3098 3104
31. O Delattre J Zucman B Plougastel C Desmaze T Melot M Peter H Kovar I Joubert P de Jong G Rouleau 1992 Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours Nature 359 162 165
32. SL Dennis SS Manji DP Carrington DL Scarcella DM Ashley PJ Smith EM Algar 2002 Expression and mutation analysis of the Wilms' tumor 1 gene in human neural tumors Int J Cancer 97 713 715
33. D Driman PS Thorner ML Greenberg S Chilton-MacNeill J Squire 1994 MYCN gene amplification in rhabdomyosarcoma Cancer 73 2231 2237
34. GP Dunn AT Bruce H Ikeda LJ Old RD Schreiber 2002 Cancer immunoediting: from immunosurveillance to tumor escape Nat Immunol 3 991 998
35. VH Engelhard TN Bullock TA Colella SL Sheasley DW Mullins 2002 Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy Immunol Rev 188 136 146
36. S Euvrard J Kanitakis A Claudy 2003 Skin cancers after organ transplantation N Engl J Med 348 1681 1691
37. OJ Finn 2003 Cancer vaccines: between the idea and the reality Nat Rev Immunol 3 630 641
38. B Fisk TL Blevins JT Wharton CG Ioannides 1995 Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines J Exp Med 181 2109 2117
39. EJ Foley 1953 Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin Cancer Res 13 835 837
40. JD Frost JA Hank GH Reaman S Frierdich RC Seeger J Gan PM Anderson LJ Ettinger MS Cairo BR Blazar MD Krailo KK Matthay RA Reisfeld PM Sondel 1997 A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group Cancer 80 317 333
41. C Gambini AR Sementa L Boni CE Marino M Croce F Negri V Pistoia S Ferrini MV Corrias 2003 Expression of HER2/neu is uncommon in human neuroblastic tumors and is unrelated to tumor progression Cancer Immunol Immunother 52 116 120
42. MK Gandhi JT Tellam R Khanna 2004 Epstein-Barr virus-associated Hodgkin's lymphoma Br J Haematol 125 267 281
43. JD Geiger RJ Hutchinson LF Hohenkirk EA McKenna GA Yanik JE Levine AE Chang TM Braun JJ Mule 2001 Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression Cancer Res 61 8513 8519
44. RJ Gilbertson RH Perry PJ Kelly AD Pearson J Lunec 1997 Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma Cancer Res 57 3272 3280
45. H Haapasalo E Hyytinen P Sallinen H Helin OP Kallioniemi J Isola 1996 c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization Br J Cancer 73 620 623
46. Y Hachitanda S Toyoshima K Akazawa M Tsuneyoshi 1998 N-myc gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: its correlation with histologic features Mod Pathol 11 1222 1227
47. HL Hanson DL Donermeyer H Ikeda JM White V Shankaran LJ Old H Shiku RD Schreiber PM Allen 2000 Eradication of established tumors by CD8+ T cell adoptive immunotherapy Immunity 13 265 276
48. N Himoudi M Yan A Papanastasiou J Anderson 2008 MYCN as a target for cancer immunotherapy Cancer Immunol Immunother 57 693 700
49. DP Hughes DG Thomas TJ Giordano LH Baker KT McDonagh 2004 Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma Cancer Res 64 2047 2053
50. AB Hui KW Lo XL Yin WS Poon HK Ng 2001 Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization Lab Invest 81 717 723
51. K Hung R Hayashi A Lafond-Walker C Lowenstein D Pardoll H Levitsky 1998 The central role of CD4(+) T cells in the antitumor immune response J Exp Med 188 2357 2368
52. H Ishida T Matsumura ML Salgaller Y Ohmizono Y Kadono T Sawada 1996 MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors Int J Cancer 69 375 380
53. R Ito S Asami S Motohashi S Ootsuka Y Yamaguchi M Chin H Shichino Y Yoshida N Nemoto H Mugishima T Suzuki 2005 Significance of survivin mRNA expression in prognosis of neuroblastoma Biol Pharm Bull 28 565 568
54. JF Jacobs F Brasseur CA Hulsbergen-van de Kaa MW van de Rakt CG Figdor GJ Adema PM Hoogerbrugge PG Coulie IJ de Vries 2007 Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR Int J Cancer 120 67 74
55. JF Jacobs PM Hoogerbrugge MW de Rakt EH Aarntzen CG Figdor GJ Adema IJ de Vries 2007 Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients Pediatr Blood Cancer 49 924 927
56. JF Jacobs EH Aarntzen LA Sibelt WA Blokx AC Boullart MJ Gerritsen PM Hoogerbrugge CG Figdor GJ Adema CJ Punt IJ de Vries 2008 Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients Cancer Immunol Immunother 58 1 145 151 10.1007/s00262-008-0506-5
57. JF Jacobs OM Grauer F Brasseur PM Hoogerbrugge P Wesseling CE Gidding MW van de Rakt CG Figdor PG Coulie IJ de Vries GJ Adema 2008 Selective cancer-germline gene expression in pediatric brain tumors J Neurooncol 88 3 273 280
58. E Jaros RH Perry L Adam PJ Kelly PJ Crawford RM Kalbag AD Mendelow RP Sengupta AD Pearson 1992 Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours Br J Cancer 66 373 385
59. BH Joshi P Leland RK Puri 2003 Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-pseudomonas exotoxin fusion protein Croat Med J 44 455 462
60. Y Kajiwara F Yamasaki S Hama K Yahara H Yoshioka K Sugiyama K Arita K Kurisu 2003 Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis Cancer 97 1077 1083
61. M Kalos 2003 Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects Vaccine 21 781 786
62. K Kalwak M Ussowicz E Gorczynska D Turkiewicz J Toporski G Dobaczewski E Latos-Grazynska R Ryczan D Noworolska-Sauren A Chybicka 2003 Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors J Interferon Cytokine Res 23 173 181
63. V Karanikas C Lurquin D Colau N van Baren C De Smet B Lethe T Connerotte V Corbiere MA Demoitie D Lienard B Dreno T Velu T Boon PG Coulie 2003 Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus J Immunol 171 4898 4904
64. M Katoh R Wilmotte MC Belkouch N de Tribolet G Pizzolato PY Dietrich 2003 Survivin in brain tumors: an attractive target for immunotherapy J Neurooncol 64 71 76
65. M Kawakami K Kawakami S Takahashi M Abe RK Puri 2004 Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors Cancer 101 1036 1042
66. MH Kershaw JA Trapani MJ Smyth 1995 Cytotoxic lymphocytes redirecting the cell-mediated immune response for the therapy of cancer Ther Immunol 2 173 181
67. J Khan ML Bittner LH Saal U Teichmann DO Azorsa GC Gooden WJ Pavan JM Trent PS Meltzer 1999 cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene Proc Natl Acad Sci USA 96 13264 13269
68. U Koehl J Sorensen R Esser S Zimmermann HP Gruttner T Tonn C Seidl E Seifried T Klingebiel D Schwabe 2004 IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation Blood Cells Mol Dis 33 261 266
69. A Korshunov A Golanov V Timirgaz 2002 Immunohistochemical markers for prognosis of ependymal neoplasms J Neurooncol 58 255 270
70. M Kuroki H Shibaguchi T Imakiire K Uno K Shirota T Higuchi T Shitama H Yamada Y Hirose A Nagata 2003 Immunotherapy and gene therapy of cancer using antibodies or their genes against tumor-associated antigens Anticancer Res 23 4377 4381
71. JM Lamont CS McManamy AD Pearson SC Clifford DW Ellison 2004 Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients Clin Cancer Res 10 5482 5493
72. LA Lampson 2003 Brain tumor immunotherapy: an immunologist's perspective J Neurooncol 64 3 11
73. FF Lang DC Miller S Pisharody M Koslow EW Newcomb 1994 High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas Oncogene 9 949 954
74. SS Larin GP Georgiev SL Kiselev 2004 Gene transfer approaches in cancer immunotherapy Gene Ther 11 Suppl 1 S18 S25
75. W Leung MM Hudson DK Strickland S Phipps DK Srivastava RC Ribeiro JE Rubnitz JT Sandlund LE Kun LC Bowman BI Razzouk P Mathew P Shearer WE Evans CH Pui 2000 Late effects of treatment in survivors of childhood acute myeloid leukemia J Clin Oncol 18 3273 3279
76. MS Linet LA Ries MA Smith RE Tarone SS Devesa 1999 Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States J Natl Cancer Inst 91 1051 1058
77. G Liu H Ying G Zeng CJ Wheeler KL Black JS Yu 2004 HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells Cancer Res 64 4980 4986
78. HG Ljunggren KJ Malmberg 2007 Prospects for the use of NK cells in immunotherapy of human cancer Nat Rev Immunol 7 329 339
79. HN Lode U Pertl R Xiang G Gaedicke RA Reisfeld 2000 Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma Med Pediatr Oncol 35 641 646
80. S Lu S Wang JM Grimes-Serrano 2008 Current progress of DNA vaccine studies in humans Expert Rev Vaccines 7 175 191
81. C Mackall J Berzofsky LJ Helman 2000 Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy Clin Orthop Relat Res 373 25 31
82. CL Mackall EH Rhee EJ Read HM Khuu SF Leitman D Bernstein M Tesso LM Long D Grindler M Merino W Kopp M Tsokos JA Berzofsky LJ Helman 2008 A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas Clin Cancer Res 14 4850 4858
83. HF Mark S Brown CL Sun M Samy A Afify 1998 Fluorescent in situ hybridization detection of HER-2/neu gene amplification in rhabdomyosarcoma Pathobiology 66 59 63
84. JS Miller Y Soignier A Panoskaltsis-Mortari SA McNearney GH Yun SK Fautsch D McKenna C Le TE Defor LJ Burns PJ Orchard BR Blazar JE Wagner A Slungaard DJ Weisdorf IJ Okazaki PB McGlave 2005 Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood 105 3051 3057
85. R Miralbell M Tolnay S Bieri A Probst AP Sappino W Berchtold MS Pepper G Pizzolato 1999 Pediatric medulloblastoma: prognostic value of p53, bcl-2, Mib-1, and microvessel density J Neurooncol 45 103 110
86. S Modak NK Cheung 2005 Antibody-based targeted radiation to pediatric tumors J Nucl Med 46 Suppl 1 157S 163S
87. S Modak NK Cheung 2007 Disialoganglioside directed immunotherapy of neuroblastoma Cancer Invest 25 67 77
88. JL Murray JE Cunningham H Brewer K Mujoo AA Zukiwski DA Podoloff LP Kasi V Bhadkamkar HA Fritsche RS Benjamin 1994 Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors J Clin Oncol 12 184 193
89. K Nakachi T Hayashi K Imai Y Kusunoki 2004 Perspectives on cancer immuno-epidemiology Cancer Sci 95 921 929
90. L Novellino C Castelli G Parmiani 2005 A listing of human tumor antigens recognized by T cells: March 2004 update Cancer Immunol Immunother 54 187 207
91. Y Oda B Wehrmann K Radig H Walter I Rose W Neumann A Roessner 1995 Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression Gen Diagn Pathol 141 97 103
92. H Okada KL Low G Kohanbash HA McDonald RL Hamilton IF Pollack 2008 Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas J Neurooncol 88 3 245 250
93. F Ossendorp E Mengede M Camps R Filius CJ Melief 1998 Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors J Exp Med 187 693 702
94. IF Parney LJ Chang 2003 Cancer immunogene therapy: a review J Biomed Sci 10 37 43
95. M Pavlenko C Leder P Pisa 2005 Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens Expert Rev Vaccines 4 315 327
96. I Penn 1988 Tumors of the immunocompromised patient Annu Rev Med 39 63 73
97. U Pertl H Wodrich JM Ruehlmann SD Gillies HN Lode RA Reisfeld 2003 Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma Blood 101 649 654
98. DL Porter JH Antin 1999 The graft-versus-leukemia effects of allogeneic cell therapy Annu Rev Med 50 369 386
99. RM Ransohoff P Kivisakk G Kidd 2003 Three or more routes for leukocyte migration into the central nervous system Nat Rev Immunol 3 569 581
100. CH Rickert R Strater P Kaatsch H Wassmann H Jurgens B Dockhorn-Dworniczak W Paulus 2001 Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases Am J Pathol 158 1525 1532
101. D Ridgway 2003 The first 1000 dendritic cell vaccinees Cancer Invest 21 873 886
102. D Rimoldi P Romero S Carrel 1993 The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas Int J Cancer 54 527 528
103. L Rivoltini F Arienti A Orazi G Cefalo M Gasparini C Gambacorti-Passerini F Fossati-Bellani G Parmiani 1992 Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype Cancer Immunol Immunother 34 241 251
104. M Rodolfo R Luksch E Stockert YT Chen P Collini T Ranzani C Lombardo P Dalerba L Rivoltini F Arienti F Fossati-Bellani LJ Old G Parmiani C Castelli 2003 Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen Cancer Res 63 6948 6955
105. G Rowlinson-Busza AA Epenetos 1992 Targeted delivery of biologic and other antineoplastic agents Curr Opin Oncol 4 1142 1148
106. L Ruggeri A Mancusi M Capanni MF Martelli A Velardi 2005 Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer Curr Opin Immunol 17 211 217
107. HV Russell D Strother Z Mei D Rill E Popek E Biagi E Yvon M Brenner R Rousseau 2007 Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin J Immunother 30 227 233
108. U Sahin M Koslowski O Tureci T Eberle C Zwick B Romeike JR Moringlane K Schwechheimer W Feiden M Pfreundschuh 2000 Expression of cancer testis genes in human brain tumors Clin Cancer Res 6 3916 3922
109. T Sasaki MB Lopes GR Hankins GA Helm 2002 Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system Acta Neuropathol (Berl) 104 105 109
110. DL Scarcella CW Chow MF Gonzales C Economou F Brasseur DM Ashley 1999 Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers Clin Cancer Res 5 335 341
111. K Schwechheimer RM Laufle W Schmahl M Knodlseder H Fischer H Hofler 1994 Expression of neu/c-erbB-2 in human brain tumors Hum Pathol 25 772 780
112. NL Seibel PA Dinndorf M Bauer PM Sondel GD Hammond GH Reaman 1994 Phase I study of tumor necrosis factor-alpha and actinomycin D in pediatric patients with cancer: a Children's Cancer Group study J Immunother Emphasis Tumor Immunol 16 125 131
113. K Seino S Motohashi T Fujisawa T Nakayama M Taniguchi 2006 Natural killer T cell-mediated antitumor immune responses and their clinical applications Cancer Sci 97 807 812
114. D Serraino P Piselli C Angeletti M Scuderi G Ippolito MR Capobianchi 2005 Infection with Epstein-Barr virus and cancer: an epidemiological review J Biol Regul Homeost Agents 19 63 70
115. AJ Simpson OL Caballero A Jungbluth YT Chen LJ Old 2005 Cancer/testis antigens, gametogenesis and cancer Nat Rev Cancer 5 615 625
116. JG Sinkovics JC Horvath 2000 Vaccination against human cancers (review) Int J Oncol 16 81 96
117. A Soling P Schurr F Berthold 1999 Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma Anticancer Res 19 2205 2209
118. T Sudo T Kuramoto S Komiya A Inoue K Itoh 1997 Expression of MAGE genes in osteosarcoma J Orthop Res 15 128 132
119. JB Swann MJ Smyth 2007 Immune surveillance of tumors J Clin Invest 117 1137 1146
120. M Szybka J Bartkowiak K Zakrzewski L Polis P Liberski R Kordek 2003 Microsatellite instability and expression of DNA mismatch repair genes in malignant astrocytic tumors from adult and pediatric patients Clin Neuropathol 22 180 186
121. Y Takahashi Y Oda K Kawaguchi S Tamiya H Yamamoto S Suita M Tsuneyoshi 2004 Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma Mod Pathol 17 660 669
122. K Trieb R Lehner T Stulnig I Sulzbacher KR Shroyer 2003 Survivin expression in human osteosarcoma is a marker for survival Eur J Surg Oncol 29 379 382
123. RL Truitt V Piaskowski P Kirchner L McOlash BM Camitta JT Casper 1992 Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial J Immunother 11 274 285
124. JY Tsai H Aviv J Benevenia VT Chang F Patterson S Aisner M Hameed 2004 HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis Cancer Invest 22 16 24
125. T Tsukahara S Kawaguchi T Torigoe H Asanuma E Nakazawa K Shimozawa Y Nabeta S Kimura M Kaya S Nagoya T Wada T Yamashita N Sato 2006 Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5 Cancer Sci 97 1374 1380
126. DA Tweddle AJ Malcolm M Cole AD Pearson J Lunec 2001 p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells Am J Pathol 158 2067 2077
127. H Uchi R Stan MJ Turk ME Engelhorn GA Rizzuto SM Goldberg JD Wolchok AN Houghton 2006 Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo Adv Immunol 90 215 241
128. MM Uttenreuther-Fischer CS Huang RA Reisfeld AL Yu 1995 Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients Cancer Immunol Immunother 41 29 36
129. LT van den Broeke CD Pendleton C Mackall LJ Helman JA Berzofsky 2006 Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors Cancer Res 66 1818 1823
130. MM van Noesel R Versteeg 2004 Pediatric neuroblastomas: genetic and epigenetic 'danse macabre' Gene 325 1 15
131. MP Velders MA Markiewicz GL Eiben WM Kast 2003 CD4+ T cell matters in tumor immunity Int Rev Immunol 22 113 140
132. A Vital H Loiseau G Kantor V Daucourt G Chene F Cohadon A Rougier J Rivel C Vital 1998 p53 protein expression in grade II astrocytomas: immunohistochemical study of 100 cases with long-term follow-up Pathol Res Pract 194 831 836
133. V Vlk T Eckschlager P Kavan E Kabickova J Koutecky V Sobota J Bubenik D Pospisilova 2000 Clinical ineffectiveness of IL-2 and/or IFN alpha administration after autologous PBSC transplantation in pediatric oncological patients Pediatr Hematol Oncol 17 31 44
134. S Ward D Casey MC Labarthe M Whelan A Dalgleish H Pandha S Todryk 2002 Immunotherapeutic potential of whole tumour cells Cancer Immunol Immunother 51 351 357
135. SL Wolden KR Lamborn SF Cleary DJ Tate SS Donaldson 1998 Second cancers following pediatric Hodgkin's disease J Clin Oncol 16 536 544
136. P Yotnda H Firat F Garcia-Pons Z Garcia G Gourru JP Vernant FA Lemonnier V Leblond P Langlade-Demoyen 1998 Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia J Clin Invest 101 2290 2296
137. P Yotnda F Garcia M Peuchmaur B Grandchamp M Duval F Lemonnier E Vilmer P Langlade-Demoyen 1998 Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia J Clin Invest 102 455 462
138. C Yun S Senju H Fujita Y Tsuji A Irie S Matsushita Y Nishimura 1999 Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein Tissue Antigens 54 153 161
139. H Zhou RL Randall AR Brothman T Maxwell CM Coffin RE Goldsby 2003 Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification J Pediatr Hematol Oncol 25 27 32